Gilead Sciences, Inc. (ETR:GIS)
Germany
· Delayed Price · Currency is EUR | Market Cap | 116.83B |
| Revenue (ttm) | 26.59B |
| Net Income (ttm) | 5.52B |
| Shares Out | n/a |
| EPS (ttm) | 4.38 |
| PE Ratio | 21.17 |
| Forward PE | 13.29 |
| Dividend | 2.84 (3.03%) |
| Ex-Dividend Date | Jun 13, 2025 |
| Volume | 504 |
| Average Volume | 757 |
| Open | 96.07 |
| Previous Close | 95.58 |
| Day's Range | 93.81 - 96.07 |
| 52-Week Range | 63.27 - 111.84 |
| Beta | 0.31 |
| RSI | 46.72 |
| Earnings Date | Aug 1, 2025 |
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]
Financial Performance
In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.
Financial numbers in USD Financial StatementsNews
Gilead twice-yearly HIV prevention drug Yeztugo recommended by WHO
Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo) for HIV Prevention at IAS 2025
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead researchers and collaborators will present new Phase 3 PURPOSE trial data at IAS 2025 showing that twice-yearly lenacapavir (Yeztugo) w...
Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead researchers and collaborators will present new Phase 3 PURPOSE trial data at IAS 2025 showing tha...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
NEW YORK , July 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or the "Company") (NASDAQ: GILD). Such investors are advised t...
Gilead Sciences (GILD) Q2 Earnings to Take a Hit from Development Charges
Gilead Sciences (GILD) Q2 Earnings to Take a Hit from Development Charges
Gilead sees Q2 EPS hit from IPR&D expenses
AHF: Gilead's Greed Costs Latin America HIV Protection
MEXICO CITY--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) denounces Gilead Sciences for once again excluding Latin America and the Caribbean (LAC) from affordable access to a groundbreaking HIV p...
Gilead's Lenacapavir Plan Faces Global Hurdles As It Commits To No-Profit Access for 2 Million
Gilead Sciences, Inc . (NASDAQ: GILD) on Wednesday announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria to supply lenacapavir — Gilead’s twice-year...
Gilead's Lenacapavir Plan Faces Global Hurdles As It Commits To No-Profit Access for 2 Million
Gilead Sciences, Inc. GILD on Wednesday announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria to supply lenacapavir — Gilead's twice-yearly injectabl...
Gilead in pact to speed up access to new HIV therapy in low-income nations
Gilead, Global Fund finalize plan to supply HIV prevention drug to poor countries
Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to supply a long-acting HIV prevention drug to low-income countries, despite the ...
Synovus Financial, Gilead Sciences And More On CNBC's 'Final Trades'
In a rapidly evolving financial landscape, insights from top investment strategists and analysts can significantly influence market sentiment and investment strategies. On CNBC's “ Halftime Report Fin...
Gilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) ...
Final Trades: Synovus, Nextera Energy, Gilead and the IYF
The Investment Committee give you their top stocks to watch for the second half.
Final Trades: Synovus, Nextera Energy, Gilead and the IYF
The Investment Committee give you their top stocks to watch for the second half.
Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.
It is time for a move higher in biotech, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Closing Bell Overtime' to discuss if the biotech sector is ready for a breakout.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
NEW YORK , July 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or the "Company") (NASDAQ: GILD). Such investors are advised to...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. (“Gilead” or the “Company”) (NASDAQ: GILD). Such investors are advis...
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
nvestors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance o...
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
Gilead Sciences (NASDAQ: GILD) has outperformed the market over the past 20 years by 3.67% on an annualized basis producing an average annual return of 12.17%. Currently, Gilead Sciences has a market...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
NEW YORK , July 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or the "Company") (NASDAQ: GILD). Such investors are advised to ...
Gilead Sciences: A Mixed Bag of Opportunities and Risks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
NEW YORK, June 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. (“Gilead” or the “Company”) (NASDAQ: GILD). Such investors are advis...